Wnt signalling pathway: a new target for the treatment of osteoporosis
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The prevention and treatment of osteoporosis traditionally involves the use of antiresorptive agents that target osteoclast function. Antiresorptive therapy is not associated with a significant increase in bone mass and, thus, only partially reduces the risk of fractures. For that reason, the search for anabolic agents, which target osteoblast function, represents an urgent medical need. The first approved bone anabolic drug for the treatment of osteoporosis was teriparatide (human parathyroid hormone 1-34). Recently, both human genetics and animal studies have pointed out the role of the Wnt/LRP5 pathway as a major regulator of bone mass accrual. Wnts are secreted glycoproteins that bind to receptor complexes including low-density lipoprotein receptor-related protein (LRP)-5/6 and Frizzled proteins. A subsequent intracellular cascade of events stabilises beta-catenin, leading to its translocation into the nucleus where, associated with Tcf/Lef transcription factors, it triggers gene expression. The existence of many potential pharmacological targets in this pathway makes it attractive for bone anabolic drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608 · cited 2×
“YU VW, AMBARTSOUMIAN G, VERLINDEN L et al.: FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice.”
BackgroundFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Day, T. F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.03.016 · Cited by 1,616
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) · Nature · doi:10.1038/34848 · Cited by 1,608 · cited 1×
“Unlike Sfrps and Wif1, Dickkopf (Dkk) proteins are potent secreted Wnt antagonists that specifically block Wnt/ β-catenin signalling [71].”
BackgroundHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591 · cited 3×
“Targets (2005) 9(5) dominant HBM trait [104,106].”
BackgroundSecreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584 · cited 1×
“Today, numerous Sfrps have been described in vertebrates (for review see [69]).”
BackgroundCanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · cited 1×
“Importantly, the two main genes required for osteoclast differentiation, Csf1/M-CSF and TNF-sf11/receptor activator of NF-κB ligand (RANKL), are secreted by the osteoblast [100,101].”
Background
Cited by
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Signaling and transcriptional regulation in osteoblast commitment and differentiation
Huang, W. (2007) · Frontiers in Bioscience · doi:10.2741/2296 · Cited by 649
Zhu, S., Chen, W., Masson, A., & Li, Y.-P. (2024) · Cell Discovery · doi:10.1038/s41421-024-00689-6 · Cited by 463
miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop
Kapinas, K., Kessler, C., Ricks, T., Gronowicz, G., & Delany, A. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116137 · Cited by 396
Wnt signaling and osteoblastogenesis
Bodine, P. V. N., & Komm, B. S. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9002-4 · Cited by 285
Metadata
- Authors
- Rawadi, G., & Roman-Roman, S.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2005-09-27
- Volume
- 9
- Issue
- 5
- Pages
- 1063-1077
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2140924177
- Cited by
- 93
- References
- 32
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Wnt signalling pathway: a new target for the treatment of osteoporosis. https://app.cochat.ai/papers/10.1517/14728222.9.5.1063
- The paper
- Rawadi, G., & Roman-Roman, S. (2005). Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.9.5.1063
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.